(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company’s poster entitled: Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients has been selected for poster presentation at the 17th World Conference on Lung Cancer (“WCLC”) held in Vienna, Austria, December 4-7, 2016.
- 0 Comments
- FY2017